Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00087048
First received: July 8, 2004
Last updated: March 21, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2006
  Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)